In agreement, targeting Lrp5/6 expression in WT-CAFs (Supplementary Figure 8f), attenuated β-catenin and YAP activation (Fig. 7c and Supplementary Figure 8f) and diminished their tumour-promoting activities (Fig. 7d, e). The gene discussed is LRP5; the disease is neoplasm.